Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 10369066)

Published in Breast Cancer Res Treat on February 01, 1999

Authors

M Watanabe1, P K Wallace, T Keler, Y M Deo, C Akewanlop, D F Hayes

Author Affiliations

1: The Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.

Articles by these authors

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol (1998) 3.40

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25

Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77

The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50

Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine (2000) 2.18

The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18

The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer (2006) 2.14

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94

Early endoscopy. A guide to therapy for acute hemorrhage in the upper gastrointestinal tract. Arch Surg (1973) 1.77

New prognostic factors for breast cancer recurrence. Semin Oncol (2001) 1.77

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol (1998) 1.59

Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med (2012) 1.56

Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45

Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol (1988) 1.43

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol (2001) 1.39

Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39

We may be lost, but we're sure makin' good time. Cancer Invest (1993) 1.38

Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27

Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta (1984) 1.15

Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res (1992) 1.14

The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. Blood (1999) 1.11

Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol (1998) 1.09

Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol (1995) 1.07

Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun (1989) 1.05

Healing flare in skeletal metastases from breast cancer. Radiology (1994) 1.05

New agents and new medical treatments for advanced breast cancer. Semin Oncol (1987) 1.04

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol (1997) 1.04

Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother (1998) 1.03

Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res (1986) 1.03

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med (1996) 1.01

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol (2000) 1.00

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer (2010) 0.99

Metachromatic assay for the quantitative determination of bacterial endotoxins. Anal Biochem (1986) 0.99

Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat (2003) 0.98

Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol (1985) 0.97

Methodological considerations for implementation of lymphocyte subset analysis in a clinical reference laboratory. Ann N Y Acad Sci (1986) 0.97

Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer (1990) 0.96

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat (1999) 0.96

Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst (2000) 0.93

Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol (2013) 0.93

Adjuvant therapy for all patients with breast cancer? J Natl Cancer Inst (2001) 0.93

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood (1997) 0.93

Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol (1998) 0.93

Examination of immobilized fungal cells by phase-contrast and scanning electron microscopy. Can J Microbiol (1983) 0.92

Recruitment of myeloid and plasmacytoid dendritic cells in cervical mucosa during Chlamydia trachomatis infection. Clin Microbiol Infect (2008) 0.91

A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol (2004) 0.90

Activation of the prolactin receptor gene by promoter insertion in a Moloney murine leukemia virus-induced rat thymoma. J Virol (1992) 0.90

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer (2003) 0.90

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res (1997) 0.90

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer (2009) 0.88

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol (2001) 0.88

Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J Immunol (1995) 0.87

Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG. J Immunol (2001) 0.87

Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat (1998) 0.87

Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood (1996) 0.87

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. Br J Cancer (2013) 0.87

Anti-HPA-1a-mediated platelet phagocytosis by monocytes in vitro and its inhibition by Fc gamma receptor (FcgammaR) reactive reagents. Eur J Haematol (2003) 0.86

Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys (1999) 0.86

CAF in metastatic breast cancer: standard therapy or another effective regimen? J Clin Oncol (1987) 0.86

Longitudinal relationship of early life immunomodulatory T cell phenotype and function to development of allergic sensitization in an urban cohort. Clin Exp Allergy (2011) 0.86

Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcgammaRI), blocks phagocytosis, and modulates receptor expression. J Leukoc Biol (1997) 0.85

Human monocyte-derived dendritic cells produce macrophage colony-stimulating factor: enhancement of c-fms expression by interleukin-10. Eur J Immunol (1998) 0.84

Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res (1992) 0.83

Distinctive immunomodulatory effects of endotoxin and nontoxic lipopolysaccharide derivatives in lymphoid cell cultures. J Biol Response Mod (1987) 0.83

Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol (2000) 0.83

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res (2001) 0.83

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. J Immunol Methods (2001) 0.83

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol (1999) 0.82

Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol (1992) 0.82

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother (1999) 0.82

The major gangliosides of human peripheral blood monocytes/macrophages: absence of ganglio series structures. Glycobiology (2001) 0.82

HIV-1-infected monocytes and monocyte-derived macrophages are impaired in their ability to produce superoxide radicals. Int J Clin Lab Res (1997) 0.81

Circulating tumor markers in breast cancer. Hematol Oncol Clin North Am (1989) 0.81

Adjuvant systemic therapy for patients with node-negative tumors. Cancer (1990) 0.81

The quantitation of carbamino adduct formation of angiotensin II and bradykinin. Biophys J (1978) 0.81

Development of T-cell lines expressing functional HIV-1 envelope glycoproteins for evaluation of immune responses in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.81

Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon. Cancer (1993) 0.81

Cloning and characterization of the sisomicin-resistance gene from Micromonospora inyoensis. J Antibiot (Tokyo) (1990) 0.81

Implications for clinical management in patients with breast cancer. Long-term effects of reconstruction surgery. Cancer (1991) 0.80

Media replenishment: a tool for the analysis of high-cell density perfusion systems. Cytotechnology (1994) 0.80

Optimizing the detection of cell surface antigens on elicited or activated mouse peritoneal macrophages. Cytometry (1994) 0.80

Role of Src in the modulation of multiple adaptor proteins in FcalphaRI oxidant signaling. Blood (1999) 0.80

Ductal carcinoma in situ of the breast: a new model. J Natl Cancer Inst (1997) 0.80

High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) (1997) 0.80

Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods (2001) 0.80

Comprehensive management of disseminated breast cancer. Cancer (1990) 0.79

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res (1997) 0.79

Fc gamma RI blockade and modulation for immunotherapy. Cancer Immunol Immunother (1998) 0.79